Specialties
Vaccine Highlights
Specialties
Vaccine
Velocity Clinical sites have extensive experience in vaccine trials, with over 400 completed studies. Access to diverse patient populations, high volume enrollment strategies and PBMC capabilities are just a few success criteria. More information about experience and vaccine capabilities are described below.
Vaccine Experience
408
Total Completed Studies
24936
Enrolled Study Participants
13
Vaccine Sites
29
BARDA Funded Programs
13
Active IBC Registered Sites
3
Sties with PBMC Capabilities
Respiratory Vaccine Experience
125
Completed Influenza Studies
30
Completed Pneumonia Studies
26
Completed RSV Studies
19
Completed COVID-19 Studies
Vaccine Experience: Indication
- Avian Influenza
- Anthrax
- C-Diff
- Celiac Disease
- Chikungunya
- Dengue
- Ebola
- HCMV
- Hepatitis B
- Herpes
- Zoster
- HPV
- Influenza
- Meningitis
- Norovirus
- Pandemic
- Influenza
- (H7N1)
- Pediatric Influenza
- Pneumonia
- Respiratory Syncytial Virus
- Seasonal Influenza
- Smallpox
- Swine Influenza H1N1
- Tetanus
- Diptheria
- Pertussis
- COVID-19
Capabilities
Patients
- Highly Diverse demographics
- Group enrollment
- Access to Pediatric and Elderly Populations
Operations
- Rapid Study Start Up
- Creative use of social media and other recruitment strategies
- Innovative approaches to high volume enrollment
Facilities
- Controlled access for Study Drug with broad range of temperature storage
- PBMC Capabilities and Experience
- Fully compliant with all regulations